Compare Becton Dickinson and Co (BDX) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Quantum Computing Inc — how do they compare? Becton Dickinson and Co trades at $153.95 (market cap $41.51B), while Quantum Computing Inc trades at $8.16 (market cap $1.88B). The key difference: Becton Dickinson and Co is far larger — about 22.1× Quantum Computing Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| BDX | QUBT | |
|---|---|---|
Market Cap | $41.51B | $1.88B |
Sector | Health | Technology |
52-Week High | $185.39 | $24.62 |
52-Week Low | $135.49 | $6.31 |
Enterprise Value | $57.97B | $894.04M |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Quantum Computing Inc. (QUBT) trades at $8.00, down 7.62% amid sector-wide selling pressure. The stock shows bearish technical signals with negative moving averages but oversold RSI readings. Fundamentally, the company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, though it maintains strong analyst support with a $24.00 consensus price target representing 200% upside potential. Recent strategic acquisitions and commercial agreements highlight growth initiatives.
QUBT presents high-risk, high-reward potential with significant cash burn offset by promising technology positioning. The company's photonics-based quantum approach and government policy support provide growth catalysts, but profitability remains distant with negative margins. Investors face substantial execution risk amid competitive quantum computing landscape, though analyst consensus remains strongly bullish on long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
